CurrentUnitedHealthcarePolicy CS079.T

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy covers indications, medical necessity determinations, and coding guidance for minimally invasive procedures for GERD, achalasia, diffuse esophageal spasm, and gastroparesis including GES, pyloroplasty, POEM, and various endoscopic therapies; excludes several state-specific versions listed. This extraction is for Part 1 of 5 of the policy (CS079.T) effective April 1, 2026.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy CodePolicy CS079.T

Change TypeAdded/Updated coverage and coding; title/template update; removed state-specific language

Effective DateApr 1, 2026

Next Review Date

Key ActionDocument objective delayed gastric emptying (scintigraphy preferred) and obtain required preauthorization/medical record documentation when evaluating gastroparesis for procedures such as GES or pyloroplasty.

POLICY UPDATE CHANGES

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases' and template updated; removed state-specific (Louisiana) content.

GES therapy is proven and medically necessary for refractory gastroparesis or chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis.

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for refractory gastroparesis or chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis.

Language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia was removed.

Added clarification that benefit coverage is determined by federal, state, or contractual requirements and that medical records may be required for review.

Applicable CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added to the policy.

Supporting Information sections (Description of Services, Clinical Evidence, FDA, References) updated to reflect current information.

Coverage Summary

This policy, titled Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (CS079.T), is CURRENT and effective April 1, 2026. It summarizes indications, clinical evidence, guideline positions, and coding guidance for minimally invasive procedures involving the esophagus and stomach.

The coverage stance is mixed: certain procedures are designated proven and medically necessary when criteria are met (for example, GES and pyloroplasty for refractory gastroparesis; POEM for achalasia and diffuse esophageal spasm), while other endoscopic or implantable GERD therapies and some POEM indications are considered unproven or not medically necessary pending further evidence.

Key thresholds & scope

policy_numberCS079.T

effective_date2026-04-01

Gastroparesis diagnosis requirementRequires objective evidence of clearly delayed gastric emptying in symptomatic patients; scintigraphy is the reference standard for measurement of gastric emptying.

GCSI threshold used in RCTSevere gastroparesis defined as GCSI > 2.3 used as eligibility in Martinek et al. (2022) randomized sham-controlled trial.

G-POEM success definition variationsClinical success definitions varied across studies (e.g., ≥1-point reduction in GCSI per Stojilkovic uniform criterion; ≥50% decrease in total GCSI used in Martinek RCT), leading to heterogeneous reported success rates.

scope_summaryCovers indications, medical necessity determinations, and coding guidance for minimally invasive procedures for GERD, achalasia, diffuse esophageal spasm, and gastroparesis including GES, pyloroplasty, POEM, and various endoscopic therapies; extraction is Part 1 of 5 effective April 1, 2026.

Coverage Rationale / Medical Necessity

Coverage Rationale Changes (summary)

Policy was updated to add/relocate coverage language indicating certain therapies are proven and medically necessary when criteria met:

ALL of the following

Relocated/Added proven therapies: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.
Refer to FDA section for FDA labeling and Humanitarian Device Exemption (HDE) information; language relocated from Gastrointestinal Disorders Diagnostic Procedures policy.
Added pyloroplasty coverage: Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.
Added as coverage rationale.

Provider Actions & Authorization

Prior Authorization

Prior authorization implied for device/procedure

Obtain preauthorization as required by the member’s payer prior to scheduling implantation or other device/procedure when payer processes require it. Coverage determinations may depend on federal, state, or contractual requirements; follow the payer’s prior authorization process and policies.

Obtain preauthorization per payer processes and document authorization in the medical record.

Documentation Required

Document objective delayed gastric emptying

Document objective evidence of delayed gastric emptying when evaluating gastroparesis for procedures such as GES or pyloroplasty. Gastric scintigraphy is the reference standard for measurement of gastric emptying and should be used when possible to meet the Gastroparesis diagnosis requirement.

Coding

Applicable CPT Procedures (reference list)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.

1–10 of 14

1/2

Added/Updated Applicable CPT CodesCPT

43647
43648
43659
43881
43882
64590
64595

Background & Evidence Summary

Scope: the policy covers minimally invasive treatments for gastroesophageal reflux disease (GERD), gastroparesis, achalasia, and diffuse esophageal spasm and reviews evidence, indications, and coding for devices and procedures including gastric electrical stimulation (GES), surgical pyloroplasty (open or laparoscopic), per oral endoscopic myotomy (POEM) and gastric POEM (G-POEM), and a range of endoscopic/endoluminal GERD therapies and implantation/injection techniques.

Device/procedure examples reviewed in the policy include the Enterra GES system, pyloroplasty (surgical and laparoscopic approaches), POEM (and variants such as Z-POEM and G-POEM), Stretta (radiofrequency), endoscopic plication/ suturing devices (EsophyX/TIF, MUSE, GERDx), injection/ bulking agents (Plexiglas, Durasphere), and magnetic sphincter augmentation (LINX/MSA).

Topic	Summary
GES systematic review note	Systematic reviews and HTAs report mixed/inconsistent randomized evidence and low overall quality; cohort series show symptomatic improvements but randomized trials provide little confirmation; device removal rates reported 7–12% in reviews; FDA Enterra HDE label for chronic intractable nausea/vomiting (diabetic/idiopathic).
Pyloroplasty systematic reviews	Systematic reviews report symptom and gastric emptying improvement; pyloroplasty alone ~61% success, pyloroplasty + fundoplication ~86% and some analyses suggest pyloric interventions provide more consistent symptom relief than GES.
POEM randomized trial & pooled success rates	Werner RCT (2019) showed POEM noninferior to laparoscopic Heller myotomy at 2 years (83% vs 81.7% clinical success); meta-analyses report pooled success for spastic esophageal disorders ~87% overall and diagnosis-specific rates (type III 87%, jackhammer 72%, diffuse spasm 88%).
POEM pooled adverse events / long-term series	Meta-analyses report adverse event pooled rates ~11–16% depending on diagnosis; single-center long-term case series report ~91% success at 2 years with reflux symptoms noted in a subset.
G-POEM RCT and meta-analyses	RCT (Martinek 2022) showed G-POEM superior to sham at 6 months (15/21 vs 4/20) but with 10 SAEs (3 related); systematic reviews/meta-analyses report ~70% 1-year success (Mandarino 2024) while other reviews using uniform criteria reported higher rates (Stojilkovic ~92.8% at 1 year) but overall evidence rated low/very low.
Stretta RCT	Randomized double-blind sham-controlled trial (Zerbib 2020) found no significant difference versus sham for days without heartburn, PPI use at 24 and 48 weeks; HTAs and reviews conclude low-quality evidence with uncertainty about comparative effectiveness.
LINX evidence & device removal data	Multiple RCT(s) and systematic reviews show MSA/LINX improves symptoms and PPI discontinuation compared with PPI and compares favorably with fundoplication for some outcomes; concerns include dysphagia, dilation, explantation/erosion; large series reported device removal ~2.7%; SAGES/NICE note adequate short/medium-term data but limited long-term safety.
Endoscopic plication / RCTs (EFTP/TIF)	Randomized trials (e.g., Kalapala 2022 EFTP) show symptom/QOL improvement and reduced PPI dependence (65.7% ≥50% GERD‑HRQL improvement vs 2.9% sham); systematic reviews/meta-analyses report short-term benefits but durability declines over time and objective pH findings are variable.
GERDx case series	GERDx prospective case series (n=40) reported improved GIQLI and DeMeester at 3 months, most patients improved symptom scores, 3/30 remained on daily meds and 4/40 had complications requiring intervention; Hayes brief and guidance note limited evidence and need for RCTs.
MUSE multicenter case series	MUSE multi-center case series (n=69) reported 73% with >50% GERD‑HRQL improvement at 6 months and 64.6% off daily PPI; other series report sustained improvements in a majority but early experience included two severe adverse events and longer-term durability data are limited.
Endoscopic plication long-term durability	Case series and long-term follow-up indicate symptomatic improvement up to 12 months with progressive loss of effect up to 60 months and no consistent improvement in manometry or pH; overall long-term durability uncertain.
Stretta systematic/HTA conclusions	HTAs and ECRI conclude Stretta evidence is low/very low quality; some uncontrolled series show symptom and QOL improvement up to 5+ years but RCTs show no difference vs sham and comparative effectiveness vs fundoplication is uncertain.
LINX RCT (Bell) outcomes	Bell randomized trial comparing MSA vs double-dose PPI: at 6 months MSA had 89% relief of regurgitation and 81% ≥50% GERD‑HRQL improvement vs 10% and 8% for PPI; transient dysphagia reported in 28% of MSA patients, ongoing dysphagia 4%.
LINX device removal / safety series	Large series (Smith et al.) reported device removal in 2.7% of 3,283 procedures; reasons included dysphagia, persistent reflux, and erosion; reviews note need for longer-term safety data.
EFTP randomized trial details	Kalapala RCT (EFTP) randomized PPI‑dependent GERD patients to EFTP vs sham: 65.7% in EFTP achieved ≥50% GERD‑HRQL reduction vs 2.9% sham; PPI dependence lower at 12 months in EFTP group.
MUSE case series and longer follow-up	Zacherl multicenter 6‑month MUSE study reported 73% >50% GERD‑HRQL improvement and 64.6% off daily PPI; subsequent single-center longer follow-up showed ~75% with ~50% score reduction at 6 months and durable benefit in a majority up to years though sample sizes small and early severe AEs noted.

Evidence strength, durability & key metrics

evidence_qualityOverall evidence strength rated low to moderate across interventions; many studies are single-center, observational, or have methodological limitations.

durability_evidenceLong-term durability data limited for many endoscopic and device therapies; long-term outcomes often lacking or show decline in effect over time.

POEM pooled success (SEDs)87% pooled clinical success for POEM across spastic esophageal disorders (meta-analysis).

Revision History

04/01/2026Administrative

Policy title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases' and template updated; removed Louisiana-specific language and other state-specific content relocation noted.

04/01/2026Material

Relocated language referencing FDA labeling and Humanitarian Device Exemption (HDE) and added coverage language stating gastric electrical stimulation (GES) therapy is proven and medically necessary for refractory gastroparesis or chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis.

04/01/2026Material

Added coverage rationale that surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for refractory gastroparesis or chronic intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy CodePolicy CS079.T

Change TypeAdded/Updated coverage and coding; title/template update; removed state-specific language

Effective DateApr 1, 2026

Next Review Date

On This Page

Prior Authorization

Consideration for experimental/unproven procedures

For procedures or technologies considered experimental or unproven (including G-POEM for gastroparesis, many endoscopic GERD therapies, Z-POEM for nonvalidated indications), prior authorization or medical review may be warranted where coverage policies require demonstration of failure of alternative therapies or enrollment in clinical studies. Providers should be prepared to document failed conservative treatments and the rationale for device/procedure use.

Prior authorization/medical review may be required for unproven procedures.
Document failure of alternative therapies or evidence of enrollment in clinical studies when requested.

Documentation Required

Refer to FDA labeling and contraindications for Enterra GES

Refer to FDA labeling and contraindications for the Enterra Therapy System when considering GES. Enterra is indicated under an HDE for chronic, intractable (drug-refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis in patients aged 18–70 years. Do not use Enterra in patients with gastric obstruction or pseudo-obstruction, prior gastric resection, fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

Enterra indication: chronic intractable nausea/vomiting from diabetic or idiopathic gastroparesis; age 18–70.
Listed contraindications per FDA labeling (see policy FDA section).

Documentation Required

Device-specific training and center experience

Procedures and devices (e.g., LINX, POEM, G-POEM) are generally recommended to be performed by clinicians with specific device/procedure training and at experienced or high-volume centers to optimize outcomes and competence. Document operator training and center experience when submitting records for review.

Recommend performance by clinicians with specific training and in experienced/high-volume centers.
Document proceduralist credentials and center experience in the medical record.

Documentation Required

Evidence limitations and patient selection

Evidence for several minimally invasive procedures is limited by low-quality studies, small single-center series, heterogeneous patient populations, variable definitions of success, and limited long-term data. When submitting for coverage, document prior therapies tried, details showing refractory status, and why the patient is an appropriate candidate given the evidence limitations.

Emphasize low/very-low quality evidence and variable outcome definitions.
Document prior therapies, refractory status, and rationale for patient selection.

Documentation Required

Medical records may be required

Medical records documentation may be required to assess whether the member meets clinical criteria for coverage, but submission of records does not guarantee coverage. Coverage decisions are governed by applicable federal, state, or contractual requirements; reviewers will reference those rules during medical review.

Documentation does not guarantee coverage — benefit determination governed by federal, state, or contractual requirements.
Medical records may be requested for review of clinical criteria.

Definitions / glossary: key terms used in the policy include POEM (Peroral endoscopic myotomy — endoscopic myotomy to treat achalasia and spastic esophageal disorders), G-POEM (Gastric peroral endoscopic myotomy — endoscopic pyloromyotomy for refractory gastroparesis), Enterra (Enterra Therapy System — gastric electrical stimulation device approved under HDE for chronic intractable nausea and vomiting from diabetic or idiopathic gastroparesis), LINX / MSA (Magnetic sphincter augmentation / LINX Reflux Management System), TIF / MUSE (Transoral incisionless fundoplication / Medigus Ultrasonic Surgical Endostapler), Stretta (radiofrequency energy delivery to the LES), and the conditions Gastroparesis (delayed gastric emptying), Achalasia (primary esophageal motor disorder with impaired EGJ relaxation and loss of organized peristalsis), and Diffuse Esophageal Spasm (DES) (rare motility disorder with simultaneous or uncoordinated contractions).